Cardiovascular
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
Records whose assigned subject headings cover the heart, the vasculature or the cardiovascular events and measures indexed with them. 28 of the 186 records indexed across this publication's scope carry at least one of them, covering 11 of the 17 compounds.
Assignment is mechanical. A record sits under this endpoint because the indexer attached one of the subject headings listed further down, not because anyone read it. The cell counts records. It does not report a result, a direction or a magnitude, and nothing in the corpus would let it.
Record coverage by compound and record class
| Compound | Ph 3 | Ph 2 | Ph 1 | Trial, no phase | Review | Other | All |
|---|---|---|---|---|---|---|---|
| Amylin | 0 | 0 | 0 | 0 | 0 | 1 [27] | 1 |
| Cagrilintide | 1 [7] | 0 | 0 | 0 | 0 | 0 | 1 |
| Dulaglutide | 1 [8] | 0 | 0 | 3 [9, 17, 19] | 0 | 0 | 4 |
| Eloralintide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exenatide | 0 | 0 | 0 | 1 [25] | 0 | 1 [24] | 2 |
| GLP-1 | 0 | 0 | 0 | 0 | 1 [20] | 0 | 1 |
| Liraglutide | 0 | 0 | 0 | 0 | 0 | 2 [16, 22] | 2 |
| Lixisenatide | 0 | 0 | 0 | 1 [18] | 0 | 3 [21, 23, 26] | 4 |
| Maridebart cafraglutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mazdutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Orforglipron | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Petrelintide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pramlintide | 0 | 0 | 0 | 0 | 0 | 1 [28] | 1 |
| Retatrutide | 0 | 0 | 0 | 0 | 1 [2] | 1 [1] | 2 |
| Semaglutide | 0 | 0 | 0 | 3 [6, 10, 13] | 0 | 3 [11, 12, 15] | 6 |
| Survodutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tirzepatide | 3 [4, 8, 14] | 0 | 0 | 3 [3, 5, 9] | 0 | 0 | 6 |
Column keys: Ph 3 phase 3; Ph 2 phase 2; Ph 1 phase 1; Trial, no phase trial, no phase assigned; Review review or synthesis; Other not a registered trial record. Phase is read from the publication type the indexer assigned to each record, never from its title.
A zero cell records that no indexed record for that compound carries one of these subject headings. It is the absence of a retrieved report, never the absence of the thing itself. The full record set for each compound is held on its own trial page.
Subject headings that place a record here
The full set is fixed and printed here so the assignment can be checked by hand against the method. 24 of the 24 headings in the set occur on at least one record in scope.
| Subject heading | Records |
|---|---|
| Cardiovascular Diseases | 10 |
| Stroke Volume | 7 |
| Blood Pressure | 5 |
| Heart Failure | 5 |
| Atherosclerosis | 3 |
| Diabetic Angiopathies | 3 |
| Myocardial Infarction | 3 |
| Heart Rate | 2 |
| Hypertension | 2 |
| Natriuretic Peptide, Brain | 2 |
| Acute Coronary Syndrome | 1 |
| Angina, Unstable | 1 |
| Atrial Fibrillation | 1 |
| Cardiotonic Agents | 1 |
| Echocardiography | 1 |
| Endothelial Cells | 1 |
| Heart | 1 |
| Heart Atria | 1 |
| Heart Ventricles | 1 |
| Magnetic Resonance Imaging, Cine | 1 |
| Myocardial Contraction | 1 |
| Myocardium | 1 |
| Pericardium | 1 |
| Tachycardia, Ventricular | 1 |
The records
28 distinct records, newest first within each class. A record indexed under more than one compound is listed once and named under each.
Phase 3 — 4 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 4 | pmid:39555826 | 2025 | Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Tirzepatide | Humans; Cardiovascular Diseases; Obesity; Stroke Volume; Body Mass Index; Treatment Outcome; Follow-Up Studies; Double-Blind Method |
| 7 | pmid:40544433 | 2025 | Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Cagrilintide | Humans; Hypertension; Obesity; Weight Loss; Anti-Obesity Agents; Drug Combinations; Body Mass Index; Treatment Outcome |
| 8 | pmid:41406444 | 2025 | Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England journal of medicine · Clinical Trial, Phase III, Equivalence Trial | human trial | Dulaglutide, Tirzepatide | Humans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Blood Glucose; Recombinant Fusion Proteins; Treatment Outcome; Injections, Subcutaneous; Double-Blind Method |
| 14 | pmid:38912654 | 2024 | Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity The New England journal of medicine · Clinical Trial, Phase III, research-article | human trial | Tirzepatide | Humans; Sleep Apnea, Obstructive; Obesity; Body Weight; Gastric Inhibitory Polypeptide; C-Reactive Protein; Treatment Outcome; Severity of Illness Index |
Trial, no phase assigned — 10 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 3 | pmid:39551891 | 2025 | Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Nature medicine · research-article, Randomized Controlled Trial | human trial | Tirzepatide | Humans; Obesity; Natriuretic Peptide, Brain; Peptide Fragments; C-Reactive Protein; Stroke Volume; Blood Pressure; Aged |
| 5 | pmid:39566869 | 2025 | Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy Journal of the American College of Cardiology · Multicenter Study, Randomized Controlled Trial | human trial | Tirzepatide | Heart Ventricles; Adipose Tissue; Humans; Obesity; Magnetic Resonance Imaging, Cine; Stroke Volume; Double-Blind Method; Aged |
| 6 | pmid:40162642 | 2025 | Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes The New England journal of medicine · Equivalence Trial, Multicenter Study | human trial | Semaglutide | Humans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Administration, Oral; Follow-Up Studies; Double-Blind Method; Aged; Middle Aged |
| 9 | pmid:37758044 | 2024 | Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics American heart journal · Clinical Trial Protocol, Research Support, Non-U.S. Gov't | other | Dulaglutide, Tirzepatide | Humans; Cardiovascular Diseases; Myocardial Infarction; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Double-Blind Method |
| 10 | pmid:38587233 | 2024 | Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes The New England journal of medicine · Randomized Controlled Trial | human trial | Semaglutide | Humans; Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Double-Blind Method; Glucagon-Like Peptides; Heart Failure; Glucagon-Like Peptide-1 Receptor Agonists |
| 13 | pmid:38785209 | 2024 | Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes The New England journal of medicine · Multicenter Study, Randomized Controlled Trial | human trial | Semaglutide | Humans; Diabetic Nephropathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Glomerular Filtration Rate; Injections, Subcutaneous; Double-Blind Method |
| 17 | pmid:31924562 | 2020 | The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial The lancet. Diabetes & endocrinology · Multicenter Study, Randomized Controlled Trial | human trial | Dulaglutide | Humans; Diabetic Angiopathies; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Prospective Studies; Double-Blind Method |
| 18 | pmid:30623563 | 2019 | Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes Diabetes, obesity & metabolism · Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Blood Glucose; Peptides; Placebos; Cross-Over Studies; Double-Blind Method; Blood Pressure |
| 19 | pmid:31189511 | 2019 | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet (London, England) · Multicenter Study, Randomized Controlled Trial | human trial | Dulaglutide | Humans; Cardiovascular Diseases; Myocardial Infarction; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Double-Blind Method; Aged |
| 25 | pmid:27106272 | 2016 | Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy Diabetes, obesity & metabolism · Randomized Controlled Trial | human trial | Exenatide | Myocardium; Liver; Pancreas; Heart; Pericardium; Adipose Tissue; Venoms; Humans |
Review or synthesis — 2 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 2 | pmid:41545327 | 2026 | The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities Clinical pharmacology in drug development · Review | other | Retatrutide | Animals; Humans; Cardiovascular Diseases; Obesity; Gastric Inhibitory Polypeptide; Fatty Acids; Peptides; Receptors, Glucagon |
| 20 | pmid:31422062 | 2019 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials The lancet. Diabetes & endocrinology · Meta-Analysis, Research Support, Non-U.S. Gov't | other | GLP-1 | Humans; Diabetic Nephropathies; Diabetic Angiopathies; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Treatment Outcome; Randomized Controlled Trials as Topic; Glucagon-Like Peptide-1 Receptor Agonists |
Not a registered trial record — 12 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 1 | pmid:40613938 | 2026 | Inotropic effects of retatrutide in isolated human atrial preparations Naunyn-Schmiedeberg's archives of pharmacology · research-article | other | Retatrutide | Heart Atria; Humans; Fatty Acids; Peptides; Cyclic AMP; Cardiotonic Agents; Myocardial Contraction; Dose-Response Relationship, Drug |
| 11 | pmid:38599221 | 2024 | Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Lancet (London, England) · Research Support, Non-U.S. Gov't, research-article | human trial | Semaglutide | Humans; Obesity; Stroke Volume; Treatment Outcome; Double-Blind Method; Aged; Middle Aged; Female |
| 12 | pmid:38740993 | 2024 | Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Nature medicine · Research Support, Non-U.S. Gov't, research-article | human trial | Semaglutide | Humans; Cardiovascular Diseases; Obesity; Weight Loss; Body Mass Index; Treatment Outcome; Double-Blind Method; Adult |
| 15 | pmid:39222642 | 2024 | Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials Lancet (London, England) · Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't | human trial | Semaglutide | Humans; Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Treatment Outcome; Hospitalization; Aged; Middle Aged |
| 16 | pmid:31747801 | 2020 | Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension Arteriosclerosis, thrombosis, and vascular biology · Research Support, Non-U.S. Gov't, research-article | rodent | Liraglutide | Cells, Cultured; Endothelial Cells; Animals; Mice, Inbred C57BL; Mice, Knockout; Mice; Hypertension; Disease Models, Animal |
| 21 | pmid:30292589 | 2018 | Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial The lancet. Diabetes & endocrinology · Research Support, Non-U.S. Gov't | other | Lixisenatide | Humans; Kidney Diseases; Albuminuria; Diabetes Mellitus, Type 2; Peptides; Glomerular Filtration Rate; Treatment Outcome; Middle Aged |
| 22 | pmid:27790809 | 2017 | Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial European journal of heart failure · Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Liraglutide | Humans; Atrial Fibrillation; Tachycardia, Ventricular; Diabetes Mellitus, Type 2; Chronic Disease; Disease Progression; Natriuretic Peptide, Brain; Peptide Fragments |
| 23 | pmid:28608285 | 2017 | The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype Diabetologia · Research Support, Non-U.S. Gov't | rodent | Lixisenatide | Macrophages; Animals; Mice; Diabetes Mellitus, Type 2; Insulin Resistance; Inflammation; Peptides; Atherosclerosis |
| 24 | pmid:28910237 | 2017 | Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes The New England journal of medicine · Comparative Study, research-article | human trial | Exenatide | Venoms; Humans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Peptides; Hypoglycemic Agents; Injections, Subcutaneous; Drug Administration Schedule |
| 26 | pmid:26630143 | 2015 | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome The New England journal of medicine · Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Lixisenatide | Humans; Cardiovascular Diseases; Angina, Unstable; Myocardial Infarction; Diabetes Mellitus, Type 2; Peptides; Hypoglycemic Agents; Treatment Failure |
| 27 | pmid:23794448 | 2013 | Amylin deposition in the brain: A second amyloid in Alzheimer disease? Annals of neurology · Research Support, Non-U.S. Gov't, research-article | other | Amylin | Brain; Humans; Alzheimer Disease; Diabetic Angiopathies; RNA, Messenger; Aged; Aged, 80 and over; Female |
| 28 | pmid:20094043 | 2010 | Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial Obesity (Silver Spring, Md.) · Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Pramlintide | Humans; Obesity; Weight Loss; Phentermine; Cyclobutanes; Appetite Depressants; Hypoglycemic Agents; Drug Therapy, Combination |
What this page does not say
- It does not say what any record found. Subject headings describe what a record is about, not what it concluded.
- It does not rank the compounds. The column order is fixed by record class and the row order is alphabetical, neither of which carries a judgement.
- It does not represent the literature. The counts are of records this corpus carries; the queries behind them returned 48,938 records in total across the compounds in scope.
- It is not clinical guidance, and it is not reviewed by a clinician. The disclaimer states the limits in full.